RT Journal Article
SR Electronic
T1 Protecting the kidney from complement: atypical haemolytic uraemic syndrome
JF Clinical Medicine
JO Clin Med
FD Royal College of Physicians
SP s89
OP s94
DO 10.7861/clinmedicine.14-6-s89
VO 14
IS Suppl 6
A1 Vicky Brocklebank
A1 David Kavanagh
YR 2014
UL http://www.rcpjournals.org/content/14/Suppl_6/s89.abstract
AB Atypical haemolytic uraemic syndrome is a thrombotic microangiopathy with a predominant renal phenotype. Research developments in the last 15 years have led to the elucidation of the role of complement over activation in the pathogenesis of the disease. This was to lead to the successful introduction of targeted pharmacological therapy, in the form of the complement inhibitor, eculizumab.